Literature DB >> 11158087

Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study.

A Sotto1, C M De Boever , P Fabbro-Peray, A Gouby, D Sirot, J Jourdan.   

Abstract

From November 1998 to February 1999 we prospectively evaluated the prevalence of resistance to penicillins, cephalosporins, carbapenem, quinolones, aminoglycosides, and trimethoprim-sulfamethoxazole (SXT) in 320 Escherichia coli isolates isolated from hospitalized patients with acute urinary tract infections (UTIs). We also studied for these strains risk factors for resistance to amoxicillin-clavulanic acid (AMC), fluoroquinolones (FQs), and SXT. Resistance rates were consistent with those from major recent studies reported in the literature. Multivariate analyses selected the following factors as being significantly associated with E. coli resistance: (i) for resistance to AMC, prior (1 year) UTI (odds ratio [OR] = 2.71, P = 0.006), prior (1 year) urinary catheter (OR = 2.98, P = 0.0025), and prior (6 months) antibiotic exposure (OR = 2.68, P = 0.005); (ii) for resistance to FQs male sex (OR = 3.87, P = 0.03), with a trend toward significance for age >65 years (OR = 7.67, P = 0.06) and prior (1 year) UTI (OR = 2.98, P = 0.07); and (iii) for resistance to SXT, male sex (OR = 1.91, P = 0.046), hospitalization in an intermediate-term-care unit (OR = 2.18, P = 0.008), and prior (1 year) UTI (OR = 2.03, P = 0.03). Ours results suggest that prior UTI is a common risk factor for resistance to the different antibiotics tested. Although few studies on risk factors for E. coli resistance to antibiotics have been published, careful interpretation of their findings, taking into consideration the population, infection site, and period studied, should contribute to the formulation of a better strategy that can be used to overcome antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158087      PMCID: PMC87756          DOI: 10.1128/JCM.39.2.438-444.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

Review 1.  Urinary tract infections in children. Epidemiology, evaluation, and management.

Authors:  H G Rushton
Journal:  Pediatr Clin North Am       Date:  1997-10       Impact factor: 3.278

2.  Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones.

Authors:  J Ena; M M López-Perezagua; C Martínez-Peinado; M A Cia-Barrio; I Ruíz-López
Journal:  Diagn Microbiol Infect Dis       Date:  1998-02       Impact factor: 2.803

Review 3.  Why are antibiotic resistance genes so resistant to elimination?

Authors:  A A Salyers; C F Amábile-Cuevas
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Antibiotic resistance in Spain: what can be done? Task Force of the General Direction for Health Planning of the Spanish Ministry of Health.

Authors:  F Baquero
Journal:  Clin Infect Dis       Date:  1996-10       Impact factor: 9.079

5.  Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.

Authors:  N Lehn; J Stower-Hoffmann; T Kott; C Strassner; H Wagner; M Kronke; W Schneider-Brachert
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

6.  Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.

Authors:  P Stapleton; P J Wu; A King; K Shannon; G French; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

7.  Prevalence of bacterial resistance to quinolones and other antimicrobials among avian Escherichia coli strains isolated from septicemic and healthy chickens in Spain.

Authors:  J E Blanco; M Blanco; A Mora; J Blanco
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

8.  Ciprofloxacin-resistant Escherichia coli emerging in a rehabilitation medical center.

Authors:  H N Canawati; R el-Farra; J Seymour; J Shimashita; D Dunn; J Z Montgomerie
Journal:  Diagn Microbiol Infect Dis       Date:  1997-11       Impact factor: 2.803

Review 9.  Increases in rates of resistance to trimethoprim.

Authors:  P Huovinen
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

10.  Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.

Authors:  C Peña; J M Albareda; R Pallares; M Pujol; F Tubau; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more
  22 in total

1.  Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period.

Authors:  Elisenda Miró; Ferran Navarro; Beatriz Mirelis; Montserrat Sabaté; Alba Rivera; Pere Coll; Guillem Prats
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 2.  Antibiotic resistance in pediatric urology.

Authors:  Rachel S Edlin; Hillary L Copp
Journal:  Ther Adv Urol       Date:  2014-04

3.  Adverse outcomes in nursing home residents with increased episodes of observed bacteriuria.

Authors:  Rituparna Das; Virginia Towle; Peter H Van Ness; Manisha Juthani-Mehta
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11-22       Impact factor: 3.254

4.  Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota.

Authors:  Burcu Tepekule; Pia Abel Zur Wiesch; Roger D Kouyos; Sebastian Bonhoeffer
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-30       Impact factor: 11.205

5.  Antibiotic resistance in uropathogenic e. Coli strains isolated from non-hospitalized patients in pakistan.

Authors:  Ihsan Ali; Neeraj Kumar; Safia Ahmed; Javid Iqbal Dasti
Journal:  J Clin Diagn Res       Date:  2014-09-20

6.  Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study.

Authors:  James A Karlowsky; Philippe R S Lagacé-Wiens; Patricia J Simner; Melanie R DeCorby; Heather J Adam; Andrew Walkty; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

7.  Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical study.

Authors:  Ismaël Mohammedi; Dominique Ploin; Serge Duperret; François Chapuis; Paul Petit
Journal:  Intensive Care Med       Date:  2003-05-27       Impact factor: 17.440

8.  Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea.

Authors:  B Kim; J Kim; M-R Seo; S-H Wie; Y K Cho; S-K Lim; J S Lee; K T Kwon; H Lee; H J Cheong; D W Park; S Y Ryu; M-H Chung; M Ki; H Pai
Journal:  Infection       Date:  2013-03-16       Impact factor: 3.553

9.  In-vitro and in-vivo evidence of dose-dependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial Vaccinium macrocarpon (cranberry) capsules.

Authors:  J-P Lavigne; G Bourg; C Combescure; H Botto; A Sotto
Journal:  Clin Microbiol Infect       Date:  2008-01-07       Impact factor: 8.067

10.  Antibiotic prescriptions and risk factors for antimicrobial resistance in patients hospitalized with urinary tract infection: a matched case-control study using the French health insurance database (SNDS).

Authors:  Marion Opatowski; Christian Brun-Buisson; Mehdi Touat; Jérôme Salomon; Didier Guillemot; Philippe Tuppin; Laurence Watier
Journal:  BMC Infect Dis       Date:  2021-06-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.